At Eckert & Ziegler Strahl- und Medizintechnik AG, business is going better than expected. The Berlin-based company claims to be “significantly above expectations after the first preliminary evaluations as of June 30, 2020”. Sales are estimated at 84 million euros after 89 million euros in the same period last year. Earnings of EUR 2.47 per Eckert & Ziegler share were incurred compared to the previous year’s figure of EUR 2.59.
“In spite of Corona, the Management Board expects, based on the current state of knowledge, that the consolidated profit will exceed the forecast for fiscal year 2020 published at the beginning of the year,” said the Berliner. EUR 4.00 is now expected per Eckert & Ziegler share instead of the previously forecast EUR 3.50. Sales are still expected to total EUR 170 million.
More about biotech shares on 4investors: click here
At a glance – chart and news: Eckert & Ziegler